.svg){kind=small}
Market Insights Snapshot
In May 2026, Beneleaves concentrated 91.30% of sales in Capsules, holding rank 1 in Capsules in Ohio, while Topical accounted for 7.27% and Edible 0.85%. Capsules declined 14.76% month over month and 6.01% year over year, whereas Topical fell 14.43% MoM but rose 121.00% YoY, and Edible jumped 60.26% MoM and 2231.49% YoY; Vapor Pens contracted 67.33% MoM and 90.33% YoY with just 0.58% share. With brand-level sales down 6.09% YoY and average price down 7.47% YoY to $27.85, the pattern implies dependence on a shrinking Capsules base even as emerging categories post outsized YoY rates from a small floor.
The combined 29.53 percentage points of MoM contraction across Capsules and Topical (−14.76% and −14.43%) pressured near-term mix, yet Edible’s 60.26% MoM rise and 2231.49% YoY surge signal a pivot opportunity away from a single-category anchor. Maintaining rank 1 in Capsules in Ohio alongside a 121.00% YoY lift in Topical suggests the brand can trade some share from a −6.01% YoY Capsules trend into faster-growing adjacencies; the implication is to stabilize the 91.30% Capsules exposure while nurturing Topical and Edible to rebalance revenue risk.
Competitive Landscape
Beneleaves is ranked #1 in OH Capsules in May 2026, unchanged YoY from #1, with stability that contrasts against UB GOOD advancing to #2 from #3 and posting a 62.22% YoY sales increase, while Main Street Health moved to #3 from #4 alongside a 42.03% YoY lift; meanwhile, Butterfly Effect - Grow Ohio slipped to #4 from #2 despite a 14.11% YoY sales gain, indicating that Beneleaves’ flat YoY rank at #1 and peak position in May 2026 imply a defended leadership that now faces faster-chasing #2–#3 incumbents, pressuring retention rather than expansion.
Notable Products
CBD/THC/CBG/CBC/CBN Entourage Effect Capsules 22-Pack (110mg CBD, 220mg THC, 339mg CBG, 321mg CBN, 303mg CBC) posted the steepest month-over-month decline in May 2026 at -28.4%, while CBN/THC 1:1 Hypnos + CBN Capsules 22-Pack (220mg CBN, 220mg THC) also fell -26.3% and the CBG/THC 1:1 Sativa Helios Capsules 22-Pack (220mg THC, 220mg CBG) slid -8.5%. RSO Capsules 22-Pack (660mg) held rank 1 despite a -21.3% drop, and the Sativa Helios Capsules 11-Pack (440mg) stayed at rank 2 with -20.1%, indicating leadership concentrated in SKUs that contracted together. Eight of the top ten are Capsules, and within that group Hybrid Unflavored RSO Capsules 11-Pack (110mg) grew +6.2% while RSO Capsules 30-Pack (1100mg) rose +7.6%, contrasting with the -18.4% decline for Hypnos Indica Capsules 11-Pack (440mg). The pattern implies Beneleaves is relying on an RSO-led Capsules core that can defend share through mix shifts toward value and higher-count packs even as premium multi-cannabinoid and CBN-led formats retrench.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
